(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
The name of the clinical trial for the Mosaic Vaccine Design that showed some success for vectors Ad26 and MVA
APPROACH
The name of the clinical trial that is now considered the milestone event in HIV vaccine research
RV144
The name of the clinical trial that took place around the same time as the STEP trial and attempted to induce CD8+ T cell response (terminated now)
STEP
Number of HIV+ patients achieved complete chimerism at 6 months post-transplant
69%
Name of the phase 1 trial for the HIVconsv vaccine
HIV-CORE 004
The glycoprotein that was targeted by the VAX 003 and 004 trials
gp120
Name of cell that was found to have a significant decrease after an HIV infection, response targeted in STEP trial
CD8+ T-cell
Name of the trial that used VRC01 bNAb
AMP Trial
The adjuvant that was used in the HVTN702 trial
MF59 Adjuvant
mRNA-based vaccine technology was used to create a successful vaccine for this disease:
COVID
Name of the phase 1 trial of the mRNA-based vaccine, was found to activate germline to produce the correct bNAbs
IAVI G001
Approach for HIV vaccine that targeted gp120 and gp160 and worked for Hep B vaccine
Neutralizing antibodies
The name of the drug that suppressed HIV to undetectable amounts
ART
New vaccine approach that uses RNA to produce viral protein to instigate an immune response. Method was used to produce COVID vaccine
mRNA based vaccine technology
The name of the current HIV preventative drug
PrEP
Dosage for RV144 trial
4 injections/half year
The name of the approach of using antibodies that recognizing a wide range of HIV-1 strains
bNAb
median follow-up time for survivors in this study
24.4 months
Percentage of HIV transmitted sexually
85%
The adjuvant that was used in the RV144 trial
Alum adjuvant
Vaccine approach used by RV144 trial that involved the use of a viral vector+recombinant protein
Prime Boost Strategies
percentage of patients had undetectable HIV DNA in their blood cells with complete chimerism
100%
Neutralizing antibodies were used to create a successful vaccine for this disease:
Hepatitis B
New vaccine approach that hopes to maximize T-cell epitopes and uses artificially constructed antigens
Mosaic vaccine design
Percentage of HIV transmitted non-sexually (needles, blood, mother to child)
15%
Clinical trial built on RV144, specifying to clades in South Africa and attempted to increase efficacy of RV144
HVTN 702
How many patients died due to non-relapse causes?
3
the primary cause of treatment failure in the Allogeneic Hematopoietic Cell Transplant study
Relapse of malignancy (cancer)
New vaccine approach that hopes to induce T cell response. Notable trials include HIV-CORE 004
HIVconsv Vaccine
